Vaccines Market Segmentation:
Technology Segment Analysis
mRNA vaccines are anticipated to garner 31.2% of the market share owing to their rapid development timelines and robust government funding. The potential of the technology has been proven by the success of the mRNA COVID-19 vaccines from prominent companies Moderna and Pfizer. Government and private market players are investing in making mRNA vaccines for HIV, cancer, etc. For instance, in 2023, BioNTech signed an agreement with the government in the UK to formulate a customized mRNA cancer vaccine, targeting to treat 10,000 patients.
Disease Indication Segment Analysis
The infectious disease segment is anticipated to occupy 62.8% market share, mainly due to consistent worldwide threats such as tuberculosis and malaria. Additionally, the government is also putting tremendous efforts into pandemic preparedness, boosting the segment's growth. The World Health Organization-led programs supported by the Gavi government for immunization are also bolstering the segment's growth. WHO reported in 2024 that infectious diseases registered 26.3% of the global deaths. Hence, rising emphasis on developing vaccines for infectious diseases is fueling the segment growth.
Our in-depth analysis of the global vaccines market includes the following segments:
|
Type |
|
|
Technology |
|
|
Disease Indication |
|
|
Patient Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
